The impact of ageing and changing utilization patterns on future cardiovascular drug expenditure: A pharmacoepidemiological projection approach

Pharmacoepidemiology and Drug Safety

Volumn 19, Issue 12, 2010, Pages 1276-1286

  Kildemoes, Helle Wallach ^a   Andersen, Morten ^a   Støvring, Henrik ^a  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

Cardiovascular drug expenditure; Drug treatment prevalence; Pharmacoepidemiological projection model

Indexed keywords

ANGIOTENSIN II ANTAGONIST; CARDIOVASCULAR AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGE SPECIFIC CARE; AGED; AGING; ARTICLE; DENMARK; DRUG COST; DRUG FATALITY; DRUG UTILIZATION; FEMALE; HEALTH SERVICE; HIDDEN MARKOV MODEL; HUMAN; INCIDENCE; MALE; PHARMACOEPIDEMIOLOGY; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; RESIDENT; SEX DIFFERENCE;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; AGING; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIOVASCULAR DISEASES; DENMARK; DRUG COSTS; FEMALE; HEALTH EXPENDITURES; HEALTH SERVICES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MARKOV CHAINS; MIDDLE AGED; PHARMACOEPIDEMIOLOGY; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; REGISTRIES; SEX FACTORS; YOUNG ADULT;

EID: 78649525301     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.2039     Document Type: Article

References (33)

1. Cohen J, Stolk E, Niezen M. The increasingly complex fourth hurdle for pharmaceuticals. Pharmacoeconomics 2007; 25(9): 727-734.
2. Boyle JP, Honeycutt AA, Narayan KM, et al. Projection of diabetes burden through 2050: impact of changing demography and disease prevalence in the U.S. Diabetes Care 2001; 24(11): 1936-1940.
3. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27(5): 1047-1053.
4. Clayton D, Schifflers E. Models for temporal variation in cancer rates. II: age-period-cohort models. Stat Med 1987; 6(4): 469-481.
5. Moller B, Fekjaer H, Hakulinen T, et al. Prediction of cancer incidence in the Nordic countries: empirical comparison of different approaches. Stat Med 2003; 22(17): 2751-2766.
6. Wang YC, Colditz GA, Kuntz KM. Forecasting the obesity epidemic in the aging U.S. population. Obesity (Silver Spring) 2007; 15(11): 2855-2865.
7. Honeycutt AA, Boyle JP, Broglio KR, et al. A dynamic Markov model for forecasting diabetes prevalence in the United States through 2050. Health Care Manag Sci 2003; 6(3): 155-164.
8. Manton KG, Dowd E. Models for forecasting chronic disease processes in adult and elderly populations: effects of stochasticity. J Epidemiol Biostat 1999; 4(1): 11-18.
9. Siewert U, Fendrich K, Doblhammer-Reiter G, et al. Health care consequences of demographic changes in Mecklenburg-West Pomerania: projected case numbers for age-related diseases up to the year 2020, based on the Study of Health in Pomerania (SHIP). Dtsch Arztebl Int 2010; 107(18): 328-334.
10. Kildemoes HW, Stovring H, Andersen M. Driving forces behind increasing cardiovascular drug utilization: a dynamic pharmacoepidemiological model. Br J Clin Pharmacol 2008; 66(6): 885-895.
11. Stovring H, Andersen M, Beck-Nielsen H, et al. Counting drugs to understand the disease: the case of measuring the diabetes epidemic. Popul Health Metr 2007; 5: 2.
12. Keiding N. Age-specific incidence and prevalence-a statistical perspective. J R Stat Soc Ser A Stat Soc 1991; 154: 371-412.
13. Kildemoes HW, Sorensen HT, Hallas J. The Danish national prescription registry. Scand J Public Health 2010 (in press).
14. WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC Classification and DDD Assignment 2004. Norway, Oslo, 2005.
15. Statistitics Denmark:, 2007.
16. Stovring H. Selection bias due to immigration in pharmacoepidemiologic studies. Pharmacoepidemiol Drug Saf 2007; 16(6): 681-686.
17. Weinstein MC, Coxson PG, Williams LW, et al. Forecasting coronary heart disease incidence, mortality, and cost: the Coronary Heart Disease Policy Model. Am J Public Health 1987; 77(11): 1417-1426.
18. Kildemoes HW, Christiansen T, Gyrd-Hansen D, Kristiansen IS, Andersen M. The impact of population ageing on future Danish drug expenditure. Health Policy 2006; 75(3): 298-311.
19. Hoffman JM, Shah ND, Vermeulen LC, et al. Projecting future drug expenditures-2007. Am J Health Syst Pharm 2007; 64(3): 298-314.
20. Poisal JA, Truffer C, Smith S, et al. Health spending projections through 2016: modest changes obscure part D's impact. Health Aff (Millwood) 2007; 26(2): w242-w253.
21. Dubois RW, Dean BB. Evolution of clinical practice guidelines: evidence supporting expanded use of medicines. Dis Manag 2006; 9(4): 210-223.
22. Jackevicius CA, Tu K, Filate WA, Brien SE, Tu JV. Trends in cardiovascular drug utilization and drug expenditures in Canada between 1996 and 2001. Can J Cardiol 2003; 19(12): 1359-1366.
23. Giacomini MK, Cook DJ, Streiner DL, Anand SS. Using practice guidelines to allocate medical technologies-an ethics framework. Int J Technol Assess Health Care 2000; 16(4): 987-1002.
24. Getz L, Sigurdsson JA, Hetlevik I, et al. Estimating the high risk group for cardiovascular disease in the Norwegian HUNT 2 population according to the 2003 European guidelines: modelling study. BMJ 2005; 331(7516): 551.
25. McElduff P, Jaefarnezhad M, Durrington PN. American, British and European recommendations for statins in the primary prevention of cardiovascular disease applied to British men studied prospectively. Heart 2006; 92(9): 1213-1218.
26. Manuel DG, Kwong K, Tanuseputro P, et al. Effectiveness and efficiency of different guidelines on statin treatment for preventing deaths from coronary heart disease: modelling study. BMJ 2006; 332(7555): 1419.
27. Assmann G, Benecke H, Neiss A, et al. Gap between guidelines and practice: attainment of treatment targets in patients with primary hypercholesterolemia starting statin therapy. Results of the 4E-Registry (Efficacy Calculation and Measurement of Cardiovascular and Cerebrovascular Events Including Physicians' Experience and Evaluation). Eur J Cardiovasc Prev Rehabil 2006; 13(5): 776-783.
28. Abookire SA, Karson AS, Fiskio J, Bates DW. Use and monitoring of "statin" lipid-lowering drugs compared with guidelines. Arch Intern Med 2001; 161(1): 53-58.
29. Mann DM, Allegrante JP, Natarajan S, Halm EA, Charlson M. Predictors of adherence to statins for primary prevention. Cardiovasc Drugs Ther 2007; 21(4): 311-316.
30. Kvan E, Pettersen KI, Landmark K, Reikvam A. Treatment with statins after acute myocardial infarction in patients >or = 80 years: underuse despite general acceptance of drug therapy for secondary prevention. Pharmacoepidemiol Drug Saf 2006; 15(4): 261-267.
31. Graham IM, Stewart M, Hertog MG. Factors impeding the implementation of cardiovascular prevention guidelines: findings from a survey conducted by the European Society of Cardiology. Eur J Cardiovasc Prev Rehabil 2006; 13(5): 839-845.
32. Walley T, Folino-Gallo P, Stephens P, Van GE. Trends in prescribing and utilization of statins and other lipid lowering drugs across Europe 1997-2003. Br J Clin Pharmacol 2005; 60(5): 543-551.
33. Pedersen KM. Pricing and reimbursement of drugs in Denmark. Eur J Health Econom 2003; 4: 60-65.